| Ytd | -64.95% | |
| 1y | -71.24% |
| Open | 1.38 | Prev Close | 1.37 | Low | 1.37 | High | 1.42 | Mkt Cap | 161.82M |
| Vol | 295.92K | Avg Vol | 382.99K | EPS | -0.70 | P/E | N/A | Forward P/E | N/A |
| Beta | 1.59 | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-20 | 50-d Avg | 1.67 | 200-d Avg | 2.41 | 1yr Est | 0.00 |
NBP News
ROCKVILLE, Md., Oct. 08, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ: NBP) today announc
I-Mab (NASDAQ: NBP - Get Free Report) and Valion Bio, Inc. Common Stock (NASDAQ: VBIO - Get Free Rep
Gainers Milestone Scientific (AMEX:MLSS) stock moved upwards by 11.8% to $0.44 during Monday's
NovaBridge Biosciences (NASDAQ:NBP) held its quarterly earnings conference call on Thursday. Below i
ROCKVILLE, Md., Sept. 08, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge
ROCKVILLE, Md., Aug. 27, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge”
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates NovaBridge Biosciences (NASDAQ:NBP
NovaBridge Biosciences (NBP) Q2 2026 Earnings Call Transcript
NovaBridge Biosciences (NASDAQ:NBP) reported quarterly losses of $(0.33) per share which missed the
ROCKVILLE, Md., Aug. 20, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge”
ROCKVILLE, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge”
Woodside Energy Group (ASX: WDS) (NYSE: WDS):2026 full-year guidancePriorCurrentTotal production vol
ROCKVILLE, Md., July 24, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge”
Shares of I-Mab (NASDAQ: NBP - Get Free Report) dropped 4.9% during mid-day trading on Wednesday. Th
NovaBridge Biosciences (NASDAQ:NBP) ("NovaBridge" or the "Company"), a clinical-stag
ROCKVILLE, Md., June 29, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge”
Registrational Phase 3 Trial Expected to Begin as Early as Q4 2026Detailed Phase 1b Data Expected to
Registrational Phase 3 Trial Expected to Begin as Early as Q4 2026 Detailed Phase 1b Data Expected t
ROCKVILLE, Md., May 28, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or
ROCKVILLE, Md., May 12, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or
Seasoned Biopharma leader bringing deep commercial experience to shape and inform corporate strategy
Seasoned Biopharma leader bringing deep commercial experience to shape and inform corporate strategy
NovaBridge Biosciences remains a high-risk, catalyst-driven biotech, trading near cash value with a
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates NovaBridge Biosciences (NASDAQ:NBP
ROCKVILLE, Md., April 07, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates NovaBridge Biosciences (NASDAQ:NBP
FDA confirmed givastomig's potential eligibility for an accelerated approval pathway NovaBridge expe
NovaBridge Biosciences (NBP) Discusses Phase 2a Clinical Data and Development Plan for VIS-101 in We
NovaBridge Biosciences (NASDAQ: NBP) shares are up on Monday following the announcement of positive
NovaBridge stock jumps after VIS-101 Phase 2a study shows strong vision improvement in wet age-relat
VIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, dual
Ooma (NYSE:OOMA) shares rose 11.3% after beating Q4 earnings and revenue expectations. Other gainers
NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform com
